Evidence map›Paper›PMID 36499300›Full record

ArticleInternational journal of molecular sciences2022

Synthetic Melanin Acts as Efficient Peptide Carrier in Cancer Vaccine Strategy.

Stefania Cuzzubbo, Benoit Roch, Guillaume Darrasse-Jèze, Benoit Hosten, Manon Leclercq, Nicolas Vignal, Claire Banissi, Eric Tartour, Antoine F Carpentier

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Functionalization of and through Melanin: Strategies and Bio-Applications.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Stefania CuzzubboInserm U970, PARCC, Université Paris Cité, 75015 Paris, France.ORCID 0000-0003-0288-4607
Benoit RochAltevax Inc., Laboratoire de Recherches Biochirurgicales (Fondation Carpentier), Hôpital Européen Georges Pompidou, 75015 Paris, France.
Guillaume Darrasse-JèzeImmunology-Immunopathology-Immunotherapy (i3) Laboratory, INSERM UMR-S 959, Sorbonne Université, 75005 Paris, France.ORCID 0000-0003-3069-8211
Benoit HostenUnité Claude Kellershohn, INSERM UMR-S 1144, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), 75010 Paris, France.
Manon LeclercqAltevax Inc., Laboratoire de Recherches Biochirurgicales (Fondation Carpentier), Hôpital Européen Georges Pompidou, 75015 Paris, France.
Nicolas VignalUnité Claude Kellershohn, INSERM UMR-S 1144, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), 75010 Paris, France.
Claire BanissiAltevax Inc., Laboratoire de Recherches Biochirurgicales (Fondation Carpentier), Hôpital Européen Georges Pompidou, 75015 Paris, France.
Eric TartourInserm U970, PARCC, Université Paris Cité, 75015 Paris, France.ORCID 0000-0002-7323-468X
Antoine F CarpentierInserm U970, PARCC, Université Paris Cité, 75015 Paris, France.ORCID 0000-0003-2926-0060
Inserm · FRHôpital Européen Georges-Pompidou · FR

Funding

ARC PJA 20141201668French National Cancer Institute Plan Cancer 2018French National Cancer Institute PLBIO19-075
6 · The paper itself

Abstract

We previously reported that a novel peptide vaccine platform, based on synthetic melanin nanoaggregates, triggers strong cytotoxic immune responses and significantly suppresses tumor growth in mice. However, the mechanisms underlying such an efficacy remained poorly described. Herein, we investigated the role of dendritic cells (DCs) in presenting the antigen embedded in the vaccine formulation, as well as the potential stimulatory effect of melanin upon these cells, in vitro by coculture experiments and ELISA/flow cytometry analysis. The vaccine efficiency was evaluated in FLT3-L

Indexed as

Cancer VaccinesNeoplasmsAnimalsDendritic CellsDihydroxyphenylalanineMelaninsMiceMice, Inbred C57BLPeptidesTissue DistributionCancer VaccinesDihydroxyphenylalanineDOPA melaninMelaninsPeptidesadjuvantcancer vaccinecarrierdelivery systemdendritic cellsLangerhans cellsL-DOPAmelaninnanoparticlespeptide vaccine

Identifiers

PMID36499300
PMCPMC9738778
OpenAlexW4310995832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.